compounded tirzepatide emmitsburg Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro and unlimited messaging with providers Compounded Tirzepatide (GLP-1 / GIP)

Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est

GH releasing peptides and their role in endocrinology

Choosing the Right Approach for Hormone Optimization CJC 1295 is one of the most researched GHRH analogs discussed in the wellness community for its potential to enhance growth hormone production, recovery, and metabolism

It promotes the movement of repair cells keratinocytes, endothelial cells, and fibroblasts to injury sites (Malinda et al., 1999)

/